From: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Total direct medical cost ($)
QALY
Incremental cost ($)
Incremental QALY
ICER($/QALY)
Ref
Monotherapy
3434.834
0.501
–
Combination therapy
8424.188
0.732
4,989.354
0.231
21,553.630